公开(公告)号：US11597725B2

公开(公告)日：2023-03-07

申请号：US16617426

申请日：2018-05-25

Applicant: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.

Inventor： Dongfang Shi ,  Jianghua Zhu ,  Jie Gu ,  Xi Cheng ,  Yan Yang ,  He Zhou ,  Pengfei Li ,  Fan Wu

IPC: C07D471/04 ,  A61P19/06 ,  C07D231/56 ,  C07D487/04 ,  C07D491/052

Abstract: The present invention belongs to the field of medicinal chemistry. Specifically disclosed is a class of URAT1 inhibitors for promoting uric acid excretion, which are compounds as represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds provided by the present invention have a very good inhibitory effect on the transport of uric acid by hURAT1 in HEK293 transfected cells, and that such compounds have a good application prospect in the treatment of hyperuricemia or gout.

公开(公告)号：US11643405B2

公开(公告)日：2023-05-09

申请号：US16973443

申请日：2019-06-05

Applicant: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.

Inventor： Dongfang Shi ,  Changjin Fu ,  Xi Cheng ,  Weiwei Gong ,  Jie Gu ,  Pengfei Li ,  Min Zhang ,  Yan Yang ,  Wenqing Jin

IPC: C07D407/04 ,  A61P1/16 ,  A61K9/00 ,  A61K9/08

CPC classification number: C07D407/04 ,  A61P1/16 ,  A61K9/0053 ,  A61K9/08

Abstract: The invention discloses compounds for treatment or prevention of liver diseases. The compounds are compounds represented by a formula (I) or (II), optical isomers or pharmaceutically acceptable salts of the compounds. The compounds and optical isomers or pharmaceutically acceptable salts of the compounds can be applied to preparation of drugs for treatment or prevention of liver diseases.